IP Library Granted Patent US 8,012,695
Granted Patent B2
US 8,012,695 · App. 12/031,316 · Granted Sep 6, 2011

Methods and compositions relating to promoter regulation by MUC1 and KLF proteins

Assignee: Dana-Farber Cancer Institute, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,012,695
App. No.
12/031,316
Granted
Sep 6, 2011
Kind
B2
Abstract

This invention relates to regulation of cell signaling, cell growth, and more particularly to the regulation of cancer or inflammatory cell growth and/or activation. The invention provides methods of, and compositions useful for, inhibiting interactions between MUC1 and a kruppel-like factor (KLF), method of inhibiting interactions between a KLF protein and the p53 promoter, methods of inhibiting the interaction between MUC1 and the p53 promoter, methods of increasing p53 activity, and methods of increasing histone acetylation. The invention also provides screening methods for identifying compounds that inhibit the aforementioned interactions. Pharmaceutical compositions containing the identified compounds can be useful in treating cancers and inflammatory conditions.

Claims (4)

1. A method of identifying a compound that inhibits the binding of MUC1 to a kruppel-like factor (KLF), the method comprising:

(a) contacting a MUC1 peptide segment comprising the MUC1 cytoplasmic domain (MUC1-CD) comprising SEQ ID NO:3 with a KLF4 peptide segment comprising SEQ ID NO:7 in the presence of a candidate compound; and

(b) determining whether the candidate compound inhibits binding of the MUC1 peptide segment to the KLF peptide segment.

2. The method of claim 1 , wherein the contacting of the MUC1 peptide segment with the KLF peptide segment in the presence of the candidate compound occurs in the further presence of a p53 promoter reagent comprising a PE21 element.

Assignments (3)
CONFIRMATORY LICENSE Recorded Sep 26, 2016
From: DANA-FARBER CANCER INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR
Reel/Frame 040144/0489 →
CONFIRMATORY LICENSE Recorded Oct 21, 2015
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036921/0909 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2008
From: KUFE, DONALD W.
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 021389/0424 →
Continuity (2)
Provisional Application 60889825 · Feb 14, 2007
Related Publication 20090098054A1 · Apr 16, 2009